sr141716 has been researched along with Weight Gain in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Podlogar, B; Smith, RA; Taing, C; Tomlinson, S; Tritto, T; Zhang, Z | 1 |
| Duranti, A; LoVerme, J; Mor, M; Piomelli, D; Rivara, S; Spadoni, G; Stella, N; Tarzia, G; Tontini, A; Xu, C | 1 |
| Gerl, M; Herling, AW; Juretschke, HP; Kilp, S; Kramer, W; Neumann-Haefelin, C | 1 |
| Pacher, P | 1 |
| Chang, Y; Dale, LC; Gonzales, D; Lawrence, D; Rigotti, NA | 1 |
| Aveyard, P; Hajek, P; Inglis, J; Parsons, AC; Shraim, M | 1 |
| Faludi, G; Halmy, L; Purebl, G; Rihmer, Z | 1 |
| Lefever, TW; Rawls, SM; Walker, EA; Ward, SJ; Whiteside, GT | 1 |
| Blundell, JE; Rodgers, RJ; Tallett, AJ | 2 |
| Ballantyne, CM; Mansoori, A; Perrard, JL; Perrard, XD; Smith, CW; Wang, Q; Wu, H | 1 |
| Booij, J; Crunelle, CL; de Bruin, K; Schulz, S; van de Giessen, E; van den Brink, W; Vanderschuren, LJ | 1 |
| Essawy, S; Zaitone, SA | 1 |
| Adan, RA; Meye, FJ; Ramakers, GM; Trezza, V; Vanderschuren, LJ | 1 |
| Dourish, CT; Kennett, GA; Vickers, SP; Webster, LJ; Wyatt, A | 1 |
| Abel, N; Avraham, Y; Berry, EM; Mechoulam, R; Menachem, AB; Okun, A; Zlotarav, O | 1 |
| Tonstad, S | 1 |
| Ben-Shabat, S; Fride, E; Gobshtis, N | 1 |
| Bray, G; Hadley, RD; Henry, RR; Lillo, JL; Woods, SC | 1 |
| Babbs, AJ; Bali, U; Horswill, JG; Jeevaratnam, P; Keily, JF; Reynet, C; Shaaban, S; Wong Kai In, P | 1 |
| Bauersachs, J; Ertl, G; Fiedler, S; Neumüller, J; Pfrang, J; Schäfer, A | 1 |
3 review(s) available for sr141716 and Weight Gain
| Article | Year |
|---|---|
Interventions for preventing weight gain after smoking cessation.
Topics: Antidepressive Agents; Benzazepines; Exercise; Female; Humans; Male; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Varenicline; Weight Gain | 2009 |
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss | 2008 |
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain | 2006 |
1 trial(s) available for sr141716 and Weight Gain
| Article | Year |
|---|---|
A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Odds Ratio; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; Weight Gain; Young Adult | 2009 |
17 other study(ies) available for sr141716 and Weight Gain
| Article | Year |
|---|---|
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Topics: Animals; Anti-Obesity Agents; Body Weight; Crystallography, X-Ray; Drug Design; Eating; Humans; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Obesity; Piperidines; Pyrazoles; Pyridones; Pyrroles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Weight Gain | 2007 |
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice.
Topics: Animals; Anti-Obesity Agents; Benzyl Compounds; Body Weight; Cannabinoids; Cerebellum; Chemistry, Pharmaceutical; Drug Design; Feeding Behavior; Humans; Inhibitory Concentration 50; Mice; Models, Chemical; Pyrroles; Rats; Receptors, Cannabinoid; Weight Gain | 2009 |
Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant.
Topics: Adiposity; Animals; Dietary Carbohydrates; Eating; Female; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Magnetic Resonance Imaging; Muscle, Skeletal; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Weight Gain | 2008 |
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Topics: Animals; Atherosclerosis; Cannabinoids; Clinical Trials as Topic; Heart Diseases; Humans; Metabolic Diseases; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant; Weight Gain | 2009 |
Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.
Topics: Age Factors; Animals; Brain; Dose-Response Relationship, Drug; Drinking; Eating; Feeding Behavior; Ketanserin; Male; Piperidines; Pruritus; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Antagonists; Weight Gain | 2009 |
Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.
Topics: Animals; Appetite; Cyclobutanes; Drug Administration Schedule; Drug Therapy, Combination; Male; Piperidines; Pyrazoles; Rats; Reaction Time; Rimonabant; Satiety Response; Weight Gain | 2010 |
Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Chemokine CCL2; Diet; Dietary Fats; Disease Models, Animal; Energy Intake; Inflammation; Liver; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Gain; Weight Loss | 2011 |
Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability.
Topics: Animals; Basal Ganglia; Cannabinoid Receptor Antagonists; Dose-Response Relationship, Drug; Male; Piperidines; Pyrazoles; Random Allocation; Rats; Receptors, Dopamine D2; Reward; Rimonabant; Up-Regulation; Weight Gain | 2013 |
Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Lactones; Male; Obesity; Orlistat; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Weight Gain | 2012 |
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
Topics: Amygdala; Animals; Anxiety; Dopaminergic Neurons; Eating; GABAergic Neurons; Humans; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Ventral Tegmental Area; Weight Gain | 2013 |
Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.
Topics: Animals; Appetite Depressants; Cannabinoids; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Male; Motor Activity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Time Factors; Weight Gain | 2003 |
Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.
Topics: Animals; Body Weight; Cannabinoid Receptor Modulators; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Eating; Endocannabinoids; Feeding and Eating Disorders; Female; Food Deprivation; Glycerides; Mice; Mice, Inbred C57BL; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Species Specificity; Weight Gain | 2005 |
Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Desipramine; Female; Fluoxetine; Maze Learning; Mice; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Swimming; Time Factors; Weight Gain | 2007 |
Cardiometabolic risk modification: current trends and emerging therapies.
Topics: Adipose Tissue; Antihypertensive Agents; Appetite; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Obesity; Physician Assistants; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors; Weight Gain | 2006 |
PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.
Topics: Allosteric Regulation; Animals; Appetite Depressants; Cell Line; Cell Membrane; Cerebral Cortex; Cyclic AMP; Cyclohexanols; Dose-Response Relationship, Drug; Eating; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Male; Molecular Structure; Phenylurea Compounds; Piperidines; Pyrazoles; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Saccharomyces cerevisiae; Silicone Elastomers; Sulfur Radioisotopes; Weight Gain | 2007 |
Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats.
Topics: Animals; Anorexia; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Grooming; Habituation, Psychophysiologic; Injections, Intraperitoneal; Male; Piperidines; Pruritus; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rest; Rimonabant; Satiety Response; Time Factors; Videotape Recording; Weight Gain | 2007 |
The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats.
Topics: Animals; Anti-Inflammatory Agents; Chemokine CCL2; Chemokine CCL5; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glucose Intolerance; Inflammation Mediators; Leukocyte Count; Leukocytes; Lipids; Male; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Weight Gain | 2008 |